绝经前特发性骨质疏松症患者的脊柱体积骨密度与强度:特立帕肽后用地舒单抗的影响
本研究为随机试验的辅助分析,41名绝经前特发性骨质疏松症女性接受特立帕肽(28例)或安慰剂(11例),特立帕肽组继续治疗至24个月,安慰剂组转为特立帕肽24个月,随后33例进入地舒单抗扩展期12个月。特立帕肽后小梁体积骨密度增加25%、刚度增加21%(均P<0.001),地舒单抗后小梁体积骨密度增加10%(P<0.001)、刚度增加7%(P=0.068),序贯治疗总体小梁体积骨密度增加43%、刚度增加21%(均P<0.001)。
要点
- 特立帕肽治疗后腰椎小梁体积骨密度增加25%、刚度增加21%(均P<0.001)。
- 后续地舒单抗使小梁体积骨密度再增加10%(P<0.001),刚度增加7%(P=0.068)。
- 序贯特立帕肽和地舒单抗使小梁体积骨密度增加43%、刚度增加21%(均P<0.001)。
核心结论
- 序贯特立帕肽后地舒单抗治疗使体积密度和刚度大幅且统计学显著增加,结果令人鼓舞,支持在绝经前特发性骨质疏松症中使用该方案。
研究设计与样本
- 随机试验的辅助分析,41名绝经前特发性骨质疏松症女性随机分配至特立帕肽(20 mcg每日;n=28)或安慰剂(n=11)。
- 6个月后,特立帕肽组继续治疗18个月,安慰剂组转为特立帕肽24个月;完成特立帕肽后33例进入2B期扩展研究,接受地舒单抗(60 mg每6个月)12个月。
- 主要结局为特立帕肽后及特立帕肽结束至地舒单抗完成期间腰椎小梁体积骨密度和刚度的基线百分比变化;序贯治疗后的相应变化为次要结局。
主要发现
- 特立帕肽后小梁体积骨密度增加25%、其他体积骨密度参数及刚度增加21%(均P<0.001)。
- 地舒单抗后小梁体积骨密度增加10%(P<0.001),其他体积骨密度参数增加(P=0.03-0.001),刚度增加7%(P=0.068)。
- 序贯特立帕肽和地舒单抗后腰椎小梁体积骨密度增加43%、其他体积骨密度参数增加15-31%、刚度增加21%(均P<0.001)。
临床怎么用
- 作者认为序贯特立帕肽后地舒单抗治疗使体积密度和刚度大幅且统计学显著增加,结果令人鼓舞,支持在绝经前特发性骨质疏松症中使用该方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Premenopausal women with idiopathic osteoporosis (PreMenIOP) have marked deficits in bone density, microstructure, and strength. OBJECTIVE: To define effects of treatment with teriparatide followed by denosumab on lumbar spine (LS) volumetric bone mineral density (vBMD) and stiffness by finite element analysis assessed on central quantitative computed tomography (cQCT) scans. DESIGN, SETTINGS, AND PARTICIPANTS: Ancillary analysis of baseline, post-teriparatide, and post-denosumab cQCT scans from a randomized trial of 41 women allocated to teriparatide (20 mcg daily; n = 28) or placebo (n = 11). After 6 months, those on teriparatide continued for 18 months, and those on placebo switched to teriparatide for 24 months. After completing teriparatide, 33 enrolled in a Phase 2B extension with denosumab (60 mg every 6 months) for 12 months. MAIN OUTCOME MEASURES: Primary outcomes were percentage change from baseline in LS trabecular vBMD and stiffness after teriparatide and between end of teriparatide and completing denosumab. Percentage change from baseline in LS trabecular vBMD and stiffness after sequential teriparatide and denosumab were secondary outcomes. FINDINGS: There were large increases (all Ps < 0.001) in trabecular vBMD (25%), other vBMD parameters, and stiffness (21%) after teriparatide. Statistically significant increases in trabecular vBMD (10%; P < 0.001) and other vBMD parameters (P = 0.03-0.001) were seen after denosumab, while stiffness increased by 7% (P = 0.068). Sequential teriparatide and denosumab led to highly significant (all Ps < 0.001) increases LS trabecular vBMD (43%), other vBMD parameters (15-31%), and stiffness (21%). CONCLUSIONS: The large and statistically significant increases in volumetric density and stiffness after sequential treatment with teriparatide followed by denosumab are encouraging and support use of this regimen in PreMenIOP.
引用
- Agarwal S, Shane E, Lang T, et al. Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab. J Clin Endocrinol Metab. 2022. PMID: 35428889. doi:10.1210/clinem/dgac232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。